SAS and Carolina partner to accelerate antiviral drug development

Posted Nov 19, 2021
SAS, a leader in analytics and software services, and the University of North Carolina are teaming up to transform the drug development process to prevent infectious disease threats from turning into a pandemic like COVID-19. The partnership is focused on the work of the University’s Rapidly Emerging Antiviral Drug Development Initiative (READDI). (UNC.edu)

Related: Campus Connections

UNC Alumna at Nike endows Carolina Covenant scholarship
Ilana Finley ’00 is creating her own Tar Heel legacy by endowing a scholarship through the Carolina Covenant. After graduating with a bachelor’s degree in...
Fri Apr 19, 2024

Chapel Hill restaurants foster relationships with UNC athletes
Behind name, image, and likeness deals that have encouraged high-profile athletes to consider business sponsorships, smaller restaurants in Chapel Hill have taken a different approach...
Wed Apr 17, 2024

ESPN announces 30 for 30 documentary on UNC alum Stuart Scott
ESPN Films will produce a 30 for 30 documentary on the extraordinary life of UNC alum Stuart Scott, who had many fans of the unique...
Mon Apr 15, 2024

‘You don’t see it every day’: Crowds gather at Morehead Planetarium to watch eclipse in Chapel Hill
Crowds of people spent the day at Morehead Planetarium and Science Center in Chapel Hill to take in the solar eclipse. By midafternoon, the moon...
Mon Apr 15, 2024